259 related articles for article (PubMed ID: 17085670)
1. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
3. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
4. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
[TBL] [Abstract][Full Text] [Related]
5. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
Koll TT; Feis SS; Wright MH; Teniola MM; Richardson MM; Robles AI; Bradsher J; Capala J; Varticovski L
Mol Cancer Ther; 2008 Jul; 7(7):1985-92. PubMed ID: 18645008
[TBL] [Abstract][Full Text] [Related]
6. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
7. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
Karkoulis PK; Stravopodis DJ; Voutsinas GE
Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
[TBL] [Abstract][Full Text] [Related]
8. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
Rao R; Lee P; Fiskus W; Yang Y; Joshi R; Wang Y; Buckley K; Balusu R; Chen J; Koul S; Joshi A; Upadhyay S; Tao J; Sotomayor E; Bhalla KN
Cancer Biol Ther; 2009 Jul; 8(13):1273-80. PubMed ID: 19440035
[TBL] [Abstract][Full Text] [Related]
9. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma.
Ayrault O; Godeny MD; Dillon C; Zindy F; Fitzgerald P; Roussel MF; Beere HM
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17037-42. PubMed ID: 19805107
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
13. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Kaur G; Belotti D; Burger AM; Fisher-Nielson K; Borsotti P; Riccardi E; Thillainathan J; Hollingshead M; Sausville EA; Giavazzi R
Clin Cancer Res; 2004 Jul; 10(14):4813-21. PubMed ID: 15269157
[TBL] [Abstract][Full Text] [Related]
15. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.
Sugimoto K; Sasaki M; Isobe Y; Tsutsui M; Suto H; Ando J; Tamayose K; Ando M; Oshimi K
Oncogene; 2008 May; 27(22):3091-101. PubMed ID: 18071310
[TBL] [Abstract][Full Text] [Related]
16. Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation.
Fukumoto R; Kiang JG
Radiat Res; 2011 Sep; 176(3):333-45. PubMed ID: 21663398
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of heat shock protein (Hsp) 90 potentiates the antiproliferative and pro-apoptotic effects of 2-(4'fluoro-phenylamino)-4H-1,3-thiazine[6,5-b]indole in A2780cis cells.
Solárová Z; Kello M; Varinská L; Budovská M; Solár P
Biomed Pharmacother; 2017 Jan; 85():463-471. PubMed ID: 27887849
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
19. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Fujii Y; Kato T; Kubota N; Fujimori A; Niwa O; Okayasu R
Oncol Rep; 2010 Jan; 23(1):199-203. PubMed ID: 19956882
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.
Wong C; Chen S
Cancer Res; 2009 Nov; 69(22):8670-7. PubMed ID: 19861537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]